Roche Holding Ltd · SIX:RO
Roche — ADA 2026 Virtual Obesity IR Event
41 slides from Roche's conference presentation, Jun 8, 2026
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: ADA 2026 Virtual Obesity IR Event
ADA 2026 Virtual Obesity IR Event 8th June 2026
Slide 4: Welcome
Welcome Bruno Eschli Head of Investor Relations
Slide 5: Agenda
Agenda Welcome Bruno Eschli, Head of Investor Relations Roche obesity strategy Morten Lammert, Global Therapeutic Area Head Cardiovascular, Renal & Metabolism Obesity pipeline update Manu Chakravarthy, SVP, Global Head of Product Development Cardiovascular, Renal & Metabolism Enicepatide Ph II (103)
Slide 6: Roche obesity strategy
Roche obesity strategy Morten Lammert Global Therapeutic Area Head Cardiovascular, Renal & Metabolism
Slide 7: CVRM strategy highlights
Cardiovascular, Renal & Metabolism CVRM strategy highlights Deliver current portfolio in the near term; focus on innovation and transformative solutions for patients End-to-end disease areas Obesity OUR AMBITION Where we play Breakthrough innovation Secure a strong entry (e.g., MASH, uHTN, CVD, CKD,
Slide 8: The global obesity epidemic presents a monumental challenge
Cardiovascular, Renal & Metabolism The global obesity epidemic presents a monumental challenge Only small population currently served, with expected expansion towards preventative treatment BMI distribution, AOM eligibility and GLP-1 usage1 Illustrative Prevention of Obesity Early Tx of Obesity Obes
Slide 9: A patient-centric approach is key to meet evolving needs of PwO
Cardiovascular, Renal & Metabolism A patient-centric approach is key to meet the evolving needs of PwO Shifting from “one-size-fits-all" to tailored solutions for diverse patient needs Patient profiles based on point in AOM journey, unmet needs & GTM considerations Prevention of Obesity Early Tx of
Slide 10: We are entering the new era in the management of obesity
Cardiovascular, Renal & Metabolism We are entering the new era in the management of obesity Multiple drivers expected to unlock new patient segments and improve adherence Global AOM market by population type Key drivers of market expansion Illustrative Continued AOM users Education, disease understa
Slide 11: Obesity pipeline update
Obesity pipeline update Manu Chakravarthy SVP, Global Head of Product Development CVRM
Slide 12: On the path to a leading CVRM portfolio
Cardiovascular, Renal & Metabolism 2026: On the path to a leading CVRM portfolio that creates optionality Clinical development Molecule Indication Ph I Ph II Ph III zilebesiran1 Hypertension KARDIA-1,KARDIA-2, KARDIA-3 ZENITH Obesity +/- T2D2 103/104 ENITH-1/2 enicepatide Glycemic control Ph III to
Slide 13: Enicepatide: Potential for BIC weight loss
Cardiovascular, Renal & Metabolism Enicepatide: Potential for BIC weight loss Novel incretin agonist with unique signaling has potential to improve weight loss and glycemic control Enicepatide: Designed with biased-signaling Enicepatide development program Unbiased GLP-1RA Biased receptor modulators
Slide 14: Petrelintide: Potential to redefine weight management experience
Cardiovascular, Renal & Metabolism Petrelintide: Potential to redefine weight management experience Potential for double-digit weight loss with improved tolerability for a better experience Petrelintide: Long-acting amylin analog suitable for Petrelintide development program Q1W dosing1-3 Molecule I
Slide 15: Enicepatide + petrelintide: Complementary MoA
Cardiovascular, Renal & Metabolism Enicepatide + petrelintide: Complementary MoA; potential for BID WL Combination may achieve BID WL while maintaining acceptable and competitive tolerability profile Ph II (ZYNERGY) trial design1 Screening Treatment SFU Petrelintide dosing regimen A Petrelintide 1 P
Slide 16: CT-996: Ph II trials ongoing
Cardiovascular, Renal & Metabolism CT-996: Ph II trials of CT-996 in people with OW/OB ± T2D ongoing Oral small molecule designed to eliminate food or fasting restrictions to optimize real-world adherence CT-996: Once-daily oral dosing over 4 weeks1 CT-996 in obesity development program CT-996-201 C
Slide 17: Our near-term portfolio offers a strong foundation
Cardiovascular, Renal & Metabolism Our near-term portfolio offers a strong foundation Differentiation potential relies on the breadth of options to address patient needs Tolerability Ceiling effect on weight loss e.g. nausea/emesis is a main driver for discontinuation e.g., weight loss plateaus afte
Slide 18: CT-388 Ph II (103) results in obesity
CT-388 Ph II (103) results in obesity Ildiko Lingvay, MD, MPH, MSCS Tenured Professor of Medicine in Endocrinology; External consultant to Roche and Genentech
Slide 19: CT-388 Phase 2 48-week study poster
Poster-2813-LB CT-388, a cAMP Dual Signal-biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Reduction in People With Overweight/Obesity: a 48-week Phase 2 Study Presenter: Ildiko Lingvay, MD, MPH, MSCS Tenured Professor of Medicine University of Texas Southwestern Medical Cent
Slide 20: Disclosures
Disclosures: Presenter: IL has received research funding (paid to institution) and/or product from: Novo Nordisk, Boehringer-Ingelheim, Dexcom, Roche, Pfizer. IL received advisory/consulting fees and/or other support from: Aadvarak Therapeutics, AbbVie, Adarx, Altasciences, Alveus Therapeutics, Amge
Slide 21: Introduction and Objective
Introduction and Objective ▪ Enicepatide is a cAMP dual signal-biased glucagon-like-peptide-1 (GLP-1)/ glucose- dependent insulinotropic polypeptide (GIP) receptor agonist developed as a once-weekly, subcutaneous injection for treatment of obesity, T2D and other weight related comorbidities ▪ In the
Slide 22: Methods
Methods Double-blind, placebo-controlled, multicenter trial conducted in the USA. Placebo Primary endpoint Key eligibility criteria Percentage weight reduction from ▪ Adults aged 18–75 years 4 mg ▪ BMI ≥30 kg/m2 or BMI ≥27 with baseline to week 48† ≥1 weight‐related comorbidity Randomized* 8 mg (N=4
Slide 23: Study Design
Study Design PBO Volume-matched 4 mg 8 mg 4 mg 12 mg 5-week Enicepatide 4 mg 8 mg follow-up 2 mg period 16 mg 4 mg 8 mg 12 mg 2 mg 24 mg 16 mg 20 mg 4 mg 8 mg 12 mg 2 mg Dosing* (SC QW) EOT −3 0 2 4 8 12 16 20 24 28 32 36 40 44 48 53 Screening Week Last permitted up-titration Up-titration phase Main
Slide 24: Baseline Demographics and Participants Disposition
Baseline Demographics and Participants Disposition Baseline Demographics and Characteristics* Disposition of Study Participants Placebo Enicepatide Total Enicepatide Placebo 4 mg 8 mg 12 mg 16 mg 24 mg 4 mg 8 mg 12 mg 16 mg 24 mg (N=79) (N=467) (N=79) (N=79) (N=78) (N=77) (N=78) (N=76) (N=79) (N=78)
Slide 25: Primary Endpoint: Body Weight Reduction
Primary Endpoint: Body Weight Reduction A. Efficacy Estimand B. Treatment Estimand Placebo-adjusted ETD (95% CI) 0.00 −0.2% Adjusted Mean (95% CI) % Change −5.0 4 mg (−8.4, −1.6) in Weight From Baseline -5.00 −10.7* 8 mg (−14.0, −7.4) Enicepatide −6.7%* −11.7* 12 mg -10.00 (−15.0, −8.4) −13.4* 16 mg
Slide 26: Key Secondary Endpoints
Key Secondary Endpoints Weight Reduction Thresholds Participants Achieving Normoglycemia at Week 48 (Baseline Prediabetes Population) 100 93 96 100 90 8686 87 90 81 80 80 73.0% 7071 71 69.8% 69.2% 70 70 Participants (%) Participants (%) 60 60 52.9% 52 5152 48 50 50 45.0% 41 38 40 35 40 31 32 30 25 2
Slide 27: Safety
Safety Enicepatide Placebo (N=79) 4 mg 8 mg 12 mg 16 mg 24 mg (N=79) (N=78) (N=77) (N=78) (N=76) Participants with ≥ 1 AE, % 64 76 81 79 82 86 Number of AEs, n 195 324 356 471 455 564 Participants with ≥ 1 SAE, % 0 4 3 3 1 5 Participants with fatal events, % 0 0 0 0 0 0 Participants withdrawn from s
Slide 28: Conclusions
Conclusions ▪ In this phase 2 trial, enicepatide demonstrated clinically meaningful, statistically significant, dose-dependent weight reduction of up to −22.7% at week 48 ▪ In the enicepatide 24 mg arm, the percentage of participants achieving 10% and 20% weight reduction was 87.0% and 47.8%, respec
Slide 29: Petrelintide Ph II (ZUPREME-1) results in obesity
Petrelintide Ph II (ZUPREME-1) results in obesity Louis J. Aronne, MD Past-President of the Obesity Society, Founder and Chair Emeritus of the American Board of Obesity Medicine and Endowed Professor of Metabolic Research; External consultant to Roche and Genentech
Slide 30: Petrelintide, a human amylin analog: ZUPREME-1 efficacy and safety
Petrelintide, a human amylin analog for the treatment of obesity: efficacy and safety from the Phase 2 trial, ZUPREME-1 W. Timothy Garvey1 Lisa Connery2, Maj Dinesen3, Berith F. Hagen3, Louise Larsen3, Dan Hesse3 1University of Alabama at Birmingham, Birmingham, AL, USA; 2AMR Clinical, Norman, Ok, U
Slide 31: W. Timothy Garvey, MD disclosures
W. Timothy Garvey, MD Disclosures Advisory Boards: Consultant on advisory boards for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer, Fractyl Health, Zealand Pharma, Genentech/Roche, Terns Pharmaceuticals, Neurocrine Biosciences, Keros Therapeutics, Gan & Lee, Corcept Therapeutics, Graviton Bi
Slide 32: Background
Background • Obesity is a heterogeneous chronic disease for which pharmacotherapy is often required • Despite recent advances in available obesity medicines, treatment persistence outside clinical trials remains low for several reasons, including side effects1,2 • Petrelintide, a human amylin analog
Slide 33: ZUPREME-1 trial design
ZUPREME 1 trial design Randomized, double-blind, placebo-controlled, parallel-group, 10-arm, multicenter, multinational, dose-finding trial Petrelintide Dose 5 Mean baseline characteristics: Petrelintide Dose 4 • N= 485 • BMI: 37 kg/m2 Petrelintide Dose 3 • Age: 47 years • BW: 107 kg Petrelintide Do
Slide 34: Estimated change in body weight
Estimated change in body weight Primary endpoint (W28), secondary endpoint (W42): Efficacy estimand* 0 W42 Dose [95% CI] Pbo –2 Mean change (%) [95% CI] Pooled Placebo -1.7% N=81 [-3.1; -0.3] –4 Dose 1 -8.7% N=79 [-10.1; -7.3] –6 Dose 2 -9.2% N=81 [-10.6; -7.8] –8 D1 Dose 3 -10.7% D2 N=83 [-12.1; -9
Slide 35: Estimated changes in selected cardiovascular risk factors
Estimated changes in selected cardiovascular risk factors Secondary endpoints (W42): Efficacy estimand* Waist circumference (cm) hsCRP (%) Triglycerides (%) Baseline 114 cm Baseline 4.2 mg/L Baseline 1.57 mmol/L 20 10 0 0 0 -6 -4.3 -12 -2 -14 -14 -9 -10 -17 -34 -5 -18 -7.9 -39 -41 -40 -21 -4 -10.0 -
Slide 36: AE overview - pooled petrelintide vs pooled placebo
AE overview - pooled petrelintide vs pooled placebo Pooled petrelintide Pooled placebo (N=404) (N=81) 100 Pooled Petrelintide Pooled Placebo (N = 404) (N = 81) 80 70.8 69.1 Participantsa (%) 60.9 59.3 60 40 32.9 34.6 20 3.7 6.2 4.5 4.9 3.5 3.5 1.5 0 0 b b b Any AE SAEs Mild Moderate Severe Any AE le
Slide 37: AE overview – selected GI AEs
AE overview – selected GI AEs Most GI AEs with petrelintide were mild (77%) and reported during dose escalation 100 Pooled PooledPetrelintide petrelintide Pooled Placebo Pooled placebo (N(N=404) = 404) (N = (N=81) 81) 80 Participants (%) 60 40 19.6 20 6.2 7.4 7.4 6.9 6.2 3.7 3.0 0 Nausea Diarrhea Co
Slide 38: Adverse events – most common PTs
Adverse events – most common PTs (>5% participants) Petrelintide Petrelintide Petrelintide Petrelintide Petrelintide Petrelintide Placebo Preferred Term (PT) D1 D2 D3 D4 D5 Pooled Pooled (N=79) (N=81) (N=83) (N=79) (N=82) (N=404) (N=81) Nausea n (%) 15 (19.0) 10 (12.3) 19 (22.9) 12 (15.2) 23 (28.0)
Slide 39: Summary Conclusions
Summary • In this Phase 2 dose finding trial, petrelintide demonstrated statistically significant and clinically meaningful weight reduction across all dose cohorts at both Week 28 and through Week 42 in a gender-balanced population • Treatment with petrelintide was associated with improvements in c
Slide 40: Q&A
Q&A
Slide 41: Doing now what patients need next
Doing now what patients need next